LOS ANGELES -- (BUSINESS WIRE) -- Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced today the launch of a new e-prescribing platform for the medical food, Theramine. The secure online e-prescribing portal is available to healthcare providers in the United States, interested in a clinically validated, peer reviewed, non-pharmacologic alternative to narcotic and NSAID pain medications for patients suffering from pain syndromes.
Theramine is a medical food indicated for the dietary management of pain syndromes, and has been the subject of two double-blind, randomized, multi-center trials, which compared Theramine to low dose naproxen and ibuprofen. 256 subjects participated in the two studies across 10 independent sites that were randomized for treatment to receive Theramine alone (two capsules twice daily), NSAID or a combination of both. In both studies, Theramine showed a statistically significant reduction in inflammation and improvement in low back pain than either naproxen at 250mg daily or ibuprofen at 400mg daily.
“Clinical evidence suggests that by addressing the increased amino acid requirements of pain syndromes you can significantly improve pain perception and reduce inflammation,” said William Shell M.D., CEO and Chief Science Officer at Targeted Medical Pharma. “Theramine is a very useful clinical tool for physicians interested in managing pain and inflammation without the GI or cardiovascular side effects associated with NSAIDs or the addictive potential of narcotics.”
Visit https://tmedpharma.com/secure/eprescribe for more information about e-prescribing Theramine or any other Targeted Medical Pharma products.
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
Forward Looking Statement
This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.